Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677

Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) retrospective cohort study. We included patients that received CMF-like (CMF) (n=1308), Anthracycline-based (A) (1046), Anthracycline-Taxane-based (AT) (1110) and dose-dense chemotherapy (DD) (213) into this analysis. In case of N0 and 1-3 pos LN we did not observe statistically significant differences in overall (OS) and disease-free survival (DFS) between CMF/A/AT and (for 1-3 pos LN) DD. In the group of 4-10 pos LN we observe an improvement by the use of AT-based chemotherapy, which cannot further be improved by DD chemotherapy. However in the highest risk group, defined as ⩾11 pos LN, we observed a statistically significant improvement in survival by the use of DD chemotherapy. Also a statistically slightly non-significant trend towards improvement of survival parameters by the use of DD compared to AT chemotherapy could be observed. Only for G3 subtypes we could observe a survival benefit for DD. These results remain consistent after exclusion of non-guideline adherent patients (surgery, radiotherapy and endocrine therapy) in order to reduce the bias of guideline violations in other adjuvant treatment modalities. DD chemotherapy is associated with improved survival parameters in patients with ⩾11 positive LN.

Schwentner L ，Wöckel A ，König J ，Janni W ，Blettner M ，Kreienberg R ，Van Ewijk R ，BRENDA study group ... -  《-》

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.

Bulent Akinci M ，Algin E ，Inal A ，Odabas H ，Berk V ，Coskun U ，Uyeturk U ，Isikdogan A ，Aksoy S ，Civelek B ，Sevinc A ，Buyukberber S ... -  《Journal of BUON》

[Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].

Sun B ，Song ST ，Jiang ZF ，Wang T ，Zhang SH ，Meng XY ，Li XB ，Yu CZ ，Wu SK ... -  《-》

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

Hojo T ，Masuda N ，Iwamoto T ，Niikura N ，Anan K ，Aogi K ，Ohnishi T ，Yamauchi C ，Yoshida M ，Kinoshita T ，Masuoka H ，Sagara Y ，Sakatani T ，Kojima Y ，Tsuda H ，Kumamaru H ，Miyata H ，Nakamura S ... -  《-》

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.

Watanuki R ，Hayashida T ，Kawai Y ，Kikuchi M ，Nakashoji A ，Yokoe T ，Toyota T ，Seki T ，Takahashi M ，Kitagawa Y ... -  《-》